See also

References

1. ^Dart RC (2004)."Monoamine Oxidase Inhibitors".Medical Toxicology. Lippincott Williams & Wilkins. pp. 825–.ISBN 978-0-7817-2845-4.
2. ^Stahl SM (15 May 2014).Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 783–.ISBN 978-1-107-67502-5.
3. ^^abcStraker M, Grauer H (July 1961)."Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill".Canadian Medical Association Journal.85 (3):127–130.PMC 1848140.PMID 20326829.
4. ^Kalinowsky LB, Hippius H, Klein HE (1982).Biological Treatments in Psychiatry. Grune and Stratton, Harcourt Brace Jovanovich.ISBN 978-0-8089-1423-5.
5. ^Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of general psychiatry, 45(2), 111–119.https://doi.org/10.1001/archpsyc.1988.01800260015002